Cingulate Inc. (CING)
Last updated: 2026-11-11 12:57:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Cingulate Inc. (CING) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.57, with a market capitalization of $64.71M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.16 to $11.89. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$64.71M | |
$4.57 | |
$1,236.00 | |
$1.80 | |
$4.56 | |
166.00 | |
120.62K | |
-- | |
$11.89 | |
$3.16 | |
-- | |
-- |
Cingulate Inc. (CING) Pre-Market Stock Price
Cingulate Inc. (CING) is trading at $4.57 in pre-market trading as of 2026-11-11 12:36:00, up 0.11% ($0.01) from the previous close of $4.56
Pre-market trading shows how investors are pricing CING before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Cingulate Inc. (CING) 7-Day Stock Price Change
Over the past seven days, Cingulate Inc. (CING) moved from $5.03 to $4.57, representing a decline of 9.24% ($0.46).
The stock traded between $4.22 and $5.14 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 128.97 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
CING 52-Week Price Position
Position in Range: 16.1%
CING is currently trading at $4.57, placing it 16.1% of the way from its 52-week low of $3.16 to its 52-week high of $11.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cingulate Inc. (CING)?
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Cingulate Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cingulate Inc. (CING) Stock on MEXC
Eligible investors can buy real shares of Cingulate Inc. (CING) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cingulate Inc. (CING) stock price today?
2.Is CING stock going up or down today?
3.What is CING pre-market price?
4.What is CING after-hours price?
5.Is CING stock trading now?
6.Where does CING sit relative to its 52-week high and low?
7.What sector is Cingulate Inc. in?
8.What is Cingulate Inc.'s market capitalization and where is it listed?
9.How is CING valued in terms of P/E ratio and EPS?
10.Does Cingulate Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CING Stock Calculator
Estimate the value between CING shares and USD.
CING Shares to USD
1.00 CING shares = 4.565 USD
Calculations are estimates based on the latest available price and are for reference only.



